Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015 (2015), Article ID 878763, 5 pages
http://dx.doi.org/10.1155/2015/878763
Case Report

Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature

1Infectious Disease Department, Wroclaw Medical University, Wroclaw, Poland
2Infectious Disease Department, Division of Infectious Disease and Hepatology, Wroclaw Medical University, Wroclaw, Poland
3Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Wroclaw, Poland

Received 2 December 2014; Accepted 9 March 2015

Academic Editor: Raffaele Palmirotta

Copyright © 2015 Monika Pazgan-Simon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. X. Bosch, J. Ribes, R. Cléries, and M. Díaz, “Epidemiology of hepatocellular carcinoma,” Clinics in Liver Disease, vol. 9, no. 2, pp. 191–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Publisher · View at Google Scholar
  4. J. W. Park, H. B. Kim, and I. J. Lee, “Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization,” Journal of Hepatology, vol. 58, no. 1, p. 195, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. B. J. Debenham, K. S. Hu, and L. B. Harrison, “Present status and future directions of intraoperative radiotherapy,” The Lancet Oncology, vol. 14, no. 11, pp. e457–e464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Verslype, O. Rosmorduc, and P. Rougier, “Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii41–vii48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Louafi, V. Boige, M. Ducreux et al., “Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study,” Cancer, vol. 109, no. 7, pp. 1384–1390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. U. Asghar and T. Meyer, “Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?” Journal of Hepatology, vol. 56, no. 3, pp. 686–695, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Rossi, F. Zoratto, A. Papa et al., “Current approach in the treatment of hepatocellular carcinoma,” World Journal of Gastrointestinal Oncology, vol. 2, no. 9, pp. 348–359, 2010. View at Publisher · View at Google Scholar
  10. A. Zaanan, N. Williet, M. Hebbar et al., “Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study,” Journal of Hepatology, vol. 58, no. 1, pp. 81–88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B virus infection,” Journal of Hepatology, vol. 57, no. 1, pp. 167–185, 2012. View at Publisher · View at Google Scholar
  12. P. Arends, M. J. Sonneveld, R. Zoutendijk et al., “Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians,” Gut, 2014. View at Publisher · View at Google Scholar
  13. R. Zoutendijk, J. G. Reijnders, F. Zoulim et al., “Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis,” Gut, vol. 62, no. 5, pp. 760–765, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. American Association for the Study of Liver Diseases (AASLD), Practice Guidelines, American Association for the Study of Liver Diseases, 2012.
  15. T. A. Hope, M. A. Ohliger, and A. Qayyum, “MR imaging of diffuse liver disease: from technique to diagnosis,” Radiologic Clinics of North America, vol. 52, no. 4, pp. 709–724, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Masuzaki, R. Tateishi, H. Yoshida et al., “Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography,” World Journal of Gastroenterology, vol. 18, no. 12, pp. 1385–1390, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. K. S. Jung, S. U. Kim, G. H. Choi et al., “Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan),” Annals of Surgical Oncology, vol. 19, no. 13, pp. 4278–4286, 2012. View at Publisher · View at Google Scholar · View at Scopus